Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day. That was in contrast with the S&P 500 index, which increased by 0.9%.
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an up-front cash payment of $250 million, and is to be on the hook for up to $725.5 million more if and when a series of milestone payments are earned by Evergreen.
Like Lantheus, Evergreen is a highly specialized healthcare company engaged in the field of radiopharmaceuticals. These are medicines that use radioactive substances to achieve a desired effect.
Lantheus' move is part of an effort to bolster its manufacturing efforts. It wrote in the press release trumpeting the deal that "the addition of Evergreen's scalable manufacturing capabilities and infrastructure enhances Lantheus' ability to meet the complex demands of radiopharmaceutical development and production."
In the press release, Lantheus reaffirmed its existing 2024 full-year guidance. This calls for $1.51 billion to $1.52 billion in revenue, filtering down into non-GAAP (adjusted) earnings of $6.65 to $6.70 per share.
Lantheus did not specify how it would fund the Evergreen acquisition, which was probably one reason for the negative investor reaction. However, at the end of September it had more than enough to at least handle that up-front payment, with $866 million in cash on its books.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。